US 7,459,536 B1
	HGF-SF monoclonal antibody combinations
Boliang Cao, Comstock Park, Mich. (US); and George Vande Woude, Grand Rapids, Mich. (US)
Assigned to The United States of America as represented by the Secretary, Department of Health and Human Services, Washington, D.C. (US)
Appl. No. 10/129,596 PCT Filed Nov. 09, 2000, PCT No. PCT/US00/31036 § 371(c)(1), (2), (4) Date Sep. 30, 2002, PCT Pub. No. WO01/34650, PCT Pub. Date May 17, 2001.
Claims priority of provisional application 60/164173, filed on Nov. 09, 1999.
Int. Cl. C07K 16/00 (2006.01)

U.S. Cl. 530—387.1  [530/388.1; 530/388.24; 530/389.7]

8 Claims

1. A combination of anti-HGF/SF monoclonal antibodies comprising three or more anti-HGF/SF antibodies selected from the group consisting of: the monoclonal antibody produced from the hybridoma deposited under ATCC Accession No. PTA-3414, the monoclonal antibody produced from the hybridoma deposited under ATCC Accession No. PTA-3415, the monoclonal antibody produced from the hybridoma deposited-under ATCC Accession No. PTA-3416, the monoclonal antibody produced from the hybridoma deposited under ATCC Accession No. PTA-3413, and the monoclonal antibody produced from the hybridoma deposited under ATCC Accession No. PTA-3412.